Abcellera Biologics Inc (ABCL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Abcellera Biologics Inc stock (ABCL) is currently trading at $3.39. Abcellera Biologics Inc PS ratio (Price-to-Sales) is 13.72. Analyst consensus price target for ABCL is $9.17. WallStSmart rates ABCL as Sell.
- ABCL PE ratio analysis and historical PE chart
- ABCL PS ratio (Price-to-Sales) history and trend
- ABCL intrinsic value — DCF, Graham Number, EPV models
- ABCL stock price prediction 2025 2026 2027 2028 2029 2030
- ABCL fair value vs current price
- ABCL insider transactions and insider buying
- Is ABCL undervalued or overvalued?
- Abcellera Biologics Inc financial analysis — revenue, earnings, cash flow
- ABCL Piotroski F-Score and Altman Z-Score
- ABCL analyst price target and Smart Rating
Abcellera Biologics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Abcellera Biologics Inc (ABCL) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, eps growth. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Abcellera Biologics Inc (ABCL) Key Strengths (3)
Revenue surging 788.00% year-over-year
Earnings per share surging 45.90% year-over-year
Trading at 1.07x book value, attractively priced
Supporting Valuation Data
Abcellera Biologics Inc (ABCL) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 13.7x annual revenue
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 37.46%
Supporting Valuation Data
Abcellera Biologics Inc (ABCL) Detailed Analysis Report
Overall Assessment
This company scores 41/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 3 register as strengths (avg 9.3/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, EPS Growth, Price/Book. Valuation metrics including Price/Book (1.07) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 788.00%, EPS Growth at 45.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (13.72) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -14.50%, Operating Margin at -63.70%, Profit Margin at -194.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -14.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 788.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ABCL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ABCL's Price-to-Sales ratio of 13.72x trades at a deep discount to its historical average of 70.28x (17th percentile). The current valuation is 96% below its historical high of 368.64x set in Dec 2021, and 469% above its historical low of 2.41x in Oct 2023. Over the past 12 months, the PS ratio has compressed from ~24.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Abcellera Biologics Inc (ABCL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Abcellera Biologics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 75M with 788% growth year-over-year. The company is currently unprofitable, posting a -194.9% profit margin.
Key Findings
Revenue growing at 788% YoY, reaching 75M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.15 indicates a conservative balance sheet with 83M in cash.
The company is unprofitable with a -194.9% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -45M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Abcellera Biologics Inc maintain 788%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Abcellera Biologics Inc.
Bottom Line
Abcellera Biologics Inc is a high-conviction growth story with revenue accelerating at 788% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -194.9% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Abcellera Biologics Inc(ABCL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.